Kinetics of Extracellular Vesicles in Hemodialysis

Status Not yet recruiting

Clinical Trial Summary

The aim of this observational study is to gain insight into the kinetics of extracellular vesicles (EVs), derived from both in- (i.e. bio-incompatibility) and outside (tissue-injury) the extracorporeal circuit (ECC), during standard hemodialysis (HD) in adult prevalent end-stage kidney disease (ESKD) patients treated with HD. During a single HD session, blood samples for EV-assessment will be taken at several time points and at different sampling sites in the extracorporeal circuit (sampling point 1: before the rollerpump, arterial line; sampling point 2: after the rollerpump and before the dialyzer, sampling point 3: after the dialyzer, efferent line).

Clinical Trial Description

Hemodialysis (HD) is a lifesaving treatment for ESKD patients. Yet, apart from beneficial effects, HD has adverse consequences, which, apart from rapid osmolality and electrolyte shifts, results from the bio-incompatibility (BI) of the extra-corporeal circuit (ECC) and intradialytic hypotension (IDH) as well. While BI arises within the ECC due to the contact between circulating blood cells and the foreign materials of the lines and dialyzer, IDH-induced tissue injury (TI) originates within the body of the patients. Activated cells can be detected by upregulation of cell surface markers and release of degradation products. Substances which are smaller than the pores of dialyzer-membranes may pass this barrier and, thus, become undetectable in blood. Various cell types shed small particles upon activation an/or injury, so called extracellular vesicles (EVs). These EVs, which are shed by various cell types upon activation and/or injury, contain various proteins and are too large to travers dialyzer membranes. Their assessment requires strict and standardized collection and handling of blood samples. In previous HD research, both pre-analytical circumstances and analytic methods were insufficiently standardized, precluding solid conclusions. Both the contact between circulating blood cells and the ECC, and recurrent IDH, predispose to micro-inflammation and cell activation, which are related to morbidity and mortality. Hence, when analysed properly, the measuring of EVs might be a valuable tool to assess dialysis-induced adverse side-effects, not only in the dialyzer but also in the body, which, when occurring repeatedly, may influence survival. In a recent study, we found an increase in EVs during treatment with different dialysis modalities. However, EVs were only assessed before and after dialysis. Hence, in the present study, we aim to assess the kinetics of EVs in routine HD. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05957146
Study type	Observational
Source	Amsterdam UMC, location VUmc
Contact	Muriel PC Grooteman, MD PhD
Phone	+3120 566 5990
Email	mpc.grooteman@amsterdamumc.nl
Status	Not yet recruiting
Phase
Start date	August 2023
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02235571` - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients	N/A
Active, not recruiting	`NCT05027074` - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)	Phase 2
Completed	`NCT03582592` - Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis	N/A
Completed	`NCT02694068` - Biological Determinants of Peritoneal Dialysis
Not yet recruiting	`NCT02832505` - Applications of MRI in Kidney Disease
Not yet recruiting	`NCT02590081` - Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients	Phase 4
Completed	`NCT01859884` - Optimizing Kidney Transplant Informed Consent	N/A
Completed	`NCT00509236` - Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)	Phase 3
Completed	`NCT02009514` - Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients	Phase 4
Not yet recruiting	`NCT06377293` - Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients	N/A
Completed	`NCT01863914` - Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	Phase 2
Completed	`NCT01528800` - Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients	Phase 2
Withdrawn	`NCT06030050` - Animal Assisted Intervention for Hemodialysis Outpatients	N/A
Completed	`NCT04610593` - Effects of a Mindfulness-based Intervention in Stress, Pain and Quality of Life in People Undergoing Hemodialysis	N/A
Recruiting	`NCT05931276` - CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes	Phase 3
Completed	`NCT00143741` - Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers	Phase 1
Active, not recruiting	`NCT02755610` - Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis	N/A
Recruiting	`NCT03142529` - Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease	Phase 1/Phase 2
Completed	`NCT02342119` - Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation	N/A
Recruiting	`NCT05614115` - Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD	Phase 1